Stroke survivors who took GLP-1 or SGLT2 medications had a 74% lower risk of death, according to a preliminary study being presented at the American Heart Association's annual Scientific Sessions, set ...

Who will take the crown in the “miracle” GLP-1 space after a year of shortages and controversy ... Our analysis begins with a ...

A study of Gila monster venom helped start the revolution in weight-loss drugs. But scientists think that’s just the ...

Good morning, and thank you for joining us to discuss our recent business progress and review Wave's Q3 2024 financial ...

Good morning, and welcome to the Wave Life Sciences Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen only mode. As a reminder, this call is being ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after ...

MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the third quarter ended September 30, ...

The American Society for Preventive Cardiology (ASPC) announces a full program of events to be held at their annual Congress on Cardiovascular Disease Prevention, scheduled in 2025 ...

Achieved first-ever RNA editing in humans in RestorAATion-2 trial of WVE-006 (GalNAc-AIMer) in alpha-1 antitrypsin deficiency and announced ... for synergistic use with GLP-1s, and for maintenance to ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new recommendations.

GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective ...